Navigation Links
Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
Date:11/28/2007

Renowned oncologists bring decades of cancer research and clinical

development experience to Celator.

PRINCETON, N.J., Nov. 28 /PRNewswire/ -- Celator Pharmaceuticals, a biotechnology company working to develop combination chemotherapies to treat different types of cancer, today announced two recent appointments to its Scientific Advisory Board: Frederick R. Appelbaum, M.D., head of the University of Washington School of Medicine's Division of Medical Oncology and President of the Seattle Cancer Care Alliance (SCCA); and Ross C. Donehower, M.D., Professor of Oncology and Medicine at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine.

Dr. Appelbaum is the author of more than 800 articles and is active on the editorial boards of many scientific journals. He is a current or former member of a number of national scientific committees including the Board of Scientific Advisors of the National Cancer Institute. Dr. Appelbaum is a graduate of Dartmouth College and of Tufts University School of Medicine. Prior to joining the faculty of the University of Washington in 1978, Dr. Appelbaum was a clinical associate and investigator with the National Cancer Institute in Bethesda, MD.

Dr. Donehower is also Director of the Division of Medical Oncology at The Johns Hopkins Oncology Center. His clinical research has focused on the treatment of gastrointestinal and lung cancers as well as new drug development. He has authored over 150 scientific publications and sits on the editorial board of numerous prestigious scientific journals. Before joining Johns Hopkins, Dr. Donehower was a surgeon with the U.S. Public Health Service and a clinical associate with the National Cancer Institute. Dr. Donehower received his medical training at the University of Minnesota.

"We are delighted to welcome Dr. Appelbaum and Dr. Donehower to Celator's Scientific Advisory Board," said Andrew Janoff, Ph.D., CEO of Celator Pharmaceuticals. "Both of these talented individuals bring a depth of experience in cancer research and treatment that will be an enormous strategic asset for us as we work to develop new and more effective combination chemotherapies in the years ahead based on Celator's Ratiometric Dosing(TM) process."

About Celator

Celator Pharmaceuticals, Inc., is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's technology platform, represents a revolutionary new approach to the development of combination therapies based on the principle of ratiometric dosing, where drug agents are combined and maintained in the optimal ratio to target cancer cells with maximum effectiveness. The company pipeline includes: CPX-1, currently in a Phase 2 trial as a treatment option for colorectal cancer; CPX-351, currently in a Phase 1 trial as a treatment for leukemia (for information visit http://www.clinicaltrials.gov and search "Celator"); CPX-571, now positioned to advance to a Phase 1 trial and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Frederick J. Ferrer Named New CEO of The Health Trust
2. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
3. Thomson Scientific Predicts Nobel Laureates
4. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
5. Thomson Scientific Announces BONDplus for Biological Researchers
6. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
7. International Society of Hair Restoration Surgery Hosts 15th Annual Scientific Meeting in Las Vegas, September 26-30, 2007
8. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
9. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
10. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
11. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... York, NY (PRWEB) , ... May 26, 2017 , ... ... Health & Wound Care" campaign in USA Today, which will educate readers on how ... side of the campaign, a large focus is placed on melanoma. Dancing with the ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... new educational seminar to focus on current legislative activity and the latest regulatory ... at 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, ...
(Date:5/26/2017)... ... 26, 2017 , ... A new analysis of community health data reveals that ... in the Midwest. With the average cost of healthcare rising and the U.S. senior ... the quality and affordability of where they live. An annual 2017 report looked at ...
(Date:5/26/2017)... MA (PRWEB) , ... May 26, 2017 , ... On ... Act (AHCA), which narrowly passed the U.S. House on May 4, would result in ... be expected under continued implementation of the 2010 Patient Protection and Affordable Care Act ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Silver Birch of ... which is located on more than four acres of land at 5620 Sohl Avenue ... , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of the ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" Fortuna ... be the first to eliminate the need for embryonic and ... to treat neurodegenerative diseases. Fortuna announced ... Professor Michael Fehlings , MD, PhD; Father Kevin ... MD, MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)... , May 4, 2017 Clarius ... its wireless, handheld ultrasound scanners this week at ... Scientific Meeting (ACOG) in San Diego, ... "Clarius is the perfect tool for ... and heart rate, and evaluate pregnancy-related complications like ...
(Date:5/4/2017)... 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it is teaming up ... Technologies Limited to lower diabetes healthcare costs in ... card, which is available throughout all provinces and territories ... be eligible for additional savings when shopping for Dario ...
Breaking Medicine Technology: